Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences (NASDAQ:NDRA) has partnered with Hepion Pharmaceuticals (NASDAQ:HEPA) to integrate its innovative TAEUS technology into Hepion's Phase 2b trial for CRV431, targeting non-alcoholic steatohepatitis (NASH). This collaboration aims to enhance patient screening and biomarker measurement, providing a cost-effective and non-invasive method for liver fat assessment. Positive topline data has been reported from Hepion's Phase 2a AMBITION trial, with patient enrollment for the Phase 2b study set to commence in late 2021, signaling advancements in liver disease treatments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its fourth quarter 2020 financial results on March 25, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. Eastern time, allowing management to discuss the financial results and recent corporate updates. The company is known for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at diagnosing chronic liver conditions affecting over 1 billion people globally. The details for participation and access to a replay are included in the press release.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in two upcoming virtual investment conferences. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021, where management will give a presentation and hold one-on-one meetings. A recorded presentation will be available on demand from March 9, 2021. The 33rd Annual ROTH Conference will take place from March 15-19, 2021, with similar opportunities. ENDRA develops the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, aiming to improve liver health diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland, focusing on the TAEUS ultrasound device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This collaboration marks ENDRA's third clinical research partnership in Europe and aims to validate TAEUS as a non-invasive alternative to more invasive diagnostic techniques, involving 75 patients. The study data will enhance clinical evidence for TAEUS as commercialization efforts advance in Europe, alongside a recent collaboration renewal with GE Healthcare.
ENDRA Life Sciences (NASDAQ:NDRA) has been awarded U.S. Patent 10898166, enhancing its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. This patent focuses on systems for imaging biological tissue structures, complementing prior patents and expanding ENDRA's intellectual property (IP) portfolio to 80 assets. The company aims to apply TAEUS® in critical areas like Non-Alcoholic Fatty Liver Disease (NAFLD). With ongoing clinical partnerships and a commercial launch planned, ENDRA is positioning TAEUS® as a cost-effective alternative to MRI for liver condition diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted its 13th U.S. patent, number 10888898, for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers enhanced imaging capabilities for diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This patent solidifies intellectual property protection in a market where NAFLD affects 30% of the U.S. population. ENDRA's commercial launch plans include establishing international research partnerships, with recent installations in major hospitals. The company continues to expand its patent portfolio, now totaling 78 assets.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Chairman and CEO Francois Michelon will showcase the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which visualizes tissue at a fraction of the cost of MRI, aimed initially at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The presentation will be available on the company's website starting January 11 at 6:00 a.m. Eastern time and archived for 90 days.
ENDRA Life Sciences (NASDAQ:NDRA) has been granted Chinese Patent ZL 2018 8 00500526 for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. This patent, the eighth for ENDRA in China, enhances its intellectual property portfolio, now totaling 78 assets. TAEUS provides a non-invasive method to assess liver fat, crucial for the estimated 30% of China's population suffering from Non-Alcoholic Fatty Liver Disease (NAFLD). The technology offers a cost-effective alternative to MRIs and biopsies, utilizing existing ultrasound systems for patient care.
ENDRA Life Sciences (NASDAQ: NDRA) has renewed its collaboration agreement with GE Healthcare, extending the partnership until December 16, 2023. This agreement will support the commercialization of ENDRA's TAEUS technology for imaging Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Recent advancements include deployment of TAEUS systems at Rocky Vista University and UPMC, a clinical evaluation agreement in France, and an exclusive distribution deal in Vietnam for over 40 systems. ENDRA aims to enhance ultrasound capabilities and address critical clinical needs in liver assessments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has completed its public offering of 7,857,286 shares of common stock at $0.70 per share, raising $5,500,100 before expenses. The underwriter, ThinkEquity, exercised its over-allotment option for an additional 714,286 shares. The offering was made under an effective shelf registration statement filed with the SEC. ENDRA focuses on developing its TAEUS technology for improved tissue visualization, particularly for liver conditions affecting over 1 billion people globally, which currently lack practical diagnostic tools.